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ABSTRACT
The present study was undertaken to evaluate the protective effi cacy of recombinant outer membrane 
protein (OmpH) of Pasteurella multocida (B:2). The 34 kDa native OmpH protein was purifi ed from OMP-rich 
extract. Cloning, expression and purifi cation of recombinant OmpH were carried out. Protection studies in mice 
with sonicated whole cell lysate (Group I), OMP (Group II), native 34 kDa OmpH (Group III) and recombinant 
OmpH (Group IV), along with a positive (Group V; commercial vaccine) and negative control (Group VI) 
showed a survivability percentage of 83.33%, 100%, 50%, 63.67% and 83.33% in Groups I-V, respectively, 
against 100% mortality in Group VI. Serum IgG titres of 30 pooled sera samples from each of the 5 groups, 
collected at weekly intervals, was assessed using i-ELISA. In Group I, a signifi cant increase was observed in 
titres on d7, d14 and d21, having mean values (log10 titre) of 2.58, 3.93 and 4.49 respectively. In Group II, there 
was a signifi cant increase in antibody response on d7, d21 and d28, having mean values of 3.0, 4.04 and 4.41, 
respectively. In Group III, there was a signifi cant increase in titres on d7, d21 and d28, with a mean titre of 
3.70, 4.23 and 4.67, respectively. In Group IV there was a signifi cant increase in titres on d7 and d14, having 
titre values of 3.36 and 3.58, respectively. In the positive control, a signifi cant increase in titres was obtained on 
d7 and d14 with titres of 4.06 and 4.41, respectively. Taking these observations together, it may be concluded 
that OMP plays an immuno-protective role and possesses strong potential for the development of a candidate 
subunit vaccine against HS.  
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Introduction
Pasteurella multocida is a Gram negative coccobacillus that causes a wide range 
of clinical presentations within a broad host range, including pigs, sheep, goats, 
camels, deer etc. (CHRISTENSEN and BISGAARD, 2006). However it primarily affects 
water buffaloes and cattle, where it causes hemorrhagic septicaemia (HS), an acute 
and highly fatal septicaemic disease prevalent in South and South-East Asia and sub-
Saharan Africa, caused by specifi c serotypes of P. multocida  i.e. B:2 in Asia and E:2 
in Africa. In India, it is estimated to cause economic losses of more than 10 million 
rupees annually (VENKATARAMANAN et al., 2005) thus it is responsible for maximum 
mortality of livestock in the country, according to the report by the National Animal 
Diseases Referral Expert System (NADRES) of the Project Directorate on Animal 
Disease Monitoring and Surveillance (2012). The pathogenesis of the disease is due to 
complex interactions between host factors and specifi c bacterial virulence factors, such 
as: lipopolysaccharides (LPS), capsule, outer membrane proteins (OMP), fi mbrial protein 
and putative haemolysin (BOYCE et al., 2010; CHACHRA et al., 2011; YASIN et al., 2011). 
Existing vaccines, such as alum precipitated or oil adjuvanted whole cell bacterin, 
have certain limitations and the live vaccine based on an antigenically related deer 
strain of P. multocida (serotype B: 3, 4) has been questionable for its safety (MYINT and 
CARTER, 1990). A modifi ed double emulsion vaccine provided 100% protection under 
experimental conditions in rabbits (KUMAR et al., 2012). The current focus on developing 
a newer vaccine has identifi ed membrane antigens as potential immunogens in Gram 
negative bacteria (ZHOU et al., 2009; BHAT and JAIN, 2010). Likewise, OMP of P. multocida 
have been implicated as protective immunogen, as reviewed by HATFALUDI et al. (2010). 
The immunogenicity of OMP of P. multocida has been demonstrated in chickens (ZHANG 
et al., 1994; LUO et al., 1997; LUO et al., 1999; STHITMATEE et al., 2008; HERATH et al., 2010), 
calves (PATI et al., 1996; DABO et al., 1997), rabbits (CONFER et al., 2001; WASNIK et al., 
2004), goats (ZAMRI-SAAD et al., 2006) and mice (BASAGOUDANAVAR et al., 2006; LEE et 
al., 2007; KHARB and SHIV CHARAN, 2010; TAN et al., 2010; KHARB and SHIV CHARAN, 
2011; KUMAR et al., 2011). 
OmpH is a surface-exposed conserved immunodominant porin that is detected in 
100% of bovine isolates, and it has been viewed as a potential vaccine candidate (DABO 
et al., 2008). It contains a high proportion of antiparallel β-chains, giving it a barrel shape 
(CHEVALIER et al., 1993; CONFER, 1993). Work has been carried out on the prospect of 
using OmpH as a subunit vaccine in native and recombinant forms. Its protection has 
been demonstrated as a subunit or synthetic peptide vaccine against fowl cholera (LUO 
et al., 1997; LUO et al., 1999; LEE et al., 2007) and atrophic rhinitis (KIM et al., 2006). TAN 
et al. (2010) obtained high antibody titres against recombinant OmpH, using four local 
Malaysian strains of P. multocida serotype B:2. Additionally, a novel DNA vaccine 
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encoding OmpH and OmpA has been found to confer resistance against avian Pasteurella 
multocida (GONG et al., 2013). 
Therefore, the present study was carried out to evaluate the effi cacy of native and 
recombinant OmpH in providing protection against P. multocida serotype B:2.
Materials and methods
Animal. Laboratory-bred male Swiss albino mice (Mus musculus, 25-30 g), procured 
from laboratory animal house facility, IVRI, Mukteswar, were used as the experimental 
host. They were housed in a climatically controlled room and fed with standard feed 
and water ad libitum. The use of mice was approved by the Institute’s Animal Ethical 
Committee.
Bacterial strain. The vaccine strain P52 of P. multocida B:2 was obtained from the 
Biological Products Division, Indian Veterinary Research India (IVRI), Izatnagar, India 
and maintained on brain heart infusion agar enriched with 5-10% (v/v) sheep blood by 
incubating at 37 °C for 18 h.
Purifi cation of native OmpH protein. OMP-enriched fractions were extracted 
employing the standard protocol (CHOI-KIM et al., 1991) as described previously (SINGH 
et al., 2011). The OMP pellet was resuspended in PBS (pH 7.4), aliquoted and stored at 
-20 °C. Protein concentration was determined using bovine serum albumin, as standard, 
employing the method of LOWRY et al. (1951). For purifi cation of OmpH, the band 
corresponding to 34 kDa was excised from the preparative gel, of 3 mm thickness, and 
incubated in a rotary shaker at 30 °C overnight in 1 ml elution buffer (50 mM Tris-HCl, 
150 mM NaCl, and 0.1 mM EDTA; pH 7.5). Centrifugation was done at 7, 000 g for 10 
min to obtain the supernatant as OmpH. The protein was tested for the presence of single 
band in SDS-PAGE.
Expression and purifi cation of P. multocida recombinant OmpH protein. 
In order to generate recombinant OmpH, an open reading frame of OmpH was 
amplifi ed by PCR using P. multocida P52 genomic DNA as template  and the 
forward 5’-TCAGGATCCCAGCAACAGTTTACAATCAAGA-3’ and reverse 
5’-CTACCCGGGTTAGAAGTGTACGCGTAAACCA-3’ primers with BamHI and 
SmaI restriction sites. Cloning of the ompH gene was undertaken into the pQE32 
expression vector (Qiagen, USA) as per SINGH et al. (2009). The positive transformants 
were sequenced by South Campus, Delhi University (New Delhi, India) and submitted 
to the National Centre for Biotechnology Information (http://www.ncbi.nlm.nih.gov/
nuccore/HM117642; Accession No. HM117642). The plasmid carrying the ompH gene 
was transformed into E coli M15 cells and grown in Luria Bertini (LB) broth to OD600 of 
0.6. The recombinant cells were induced by adding IPTG (Promega) at 0.5 mM, 1 mM and 
1.5 mM concentration and were allowed to grow for 1 h, 2 h, 4 h and overnight, to study 
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expression kinetics. Recombinant proteins were purifi ed by affi nity chromatography with 
nickel-NTA-agarose columns (Qiagen, USA) under denaturing conditions. The purity of 
the recombinant proteins was assayed by SDS-PAGE. The experiments were conducted 
as per the protocols described earlier (SINGH et al., 2009). 
Immunization of mice.  For the vaccine study, mice were divided into six groups 
containing six mice per group. The mice in Groups I-IV were immunized with 50 μg 
of antigen with Freund’s Complete Adjuvant (FCA) on day 0 and with 50 μg of antigen 
with Freund’s Incomplete Adjuvant (FIA) (Banglore Genei, India) on day 14 by the 
subcutaneous route. Sonicated whole cell lysate, outer membrane proteins, native OmpH 
and recombinant OmpH served as immunogen for Groups I-IV, respectively. Group V 
received HS alum precipitated vaccine (Indian Immunologicals, India) and Group VI 
was given sterile PBS, pH 7.4 as control. Sera samples were collected at weekly intervals 
starting from day 0 to day 28, for evaluation of antibody response.
Challenge studies. Protective ability was assessed by direct challenge studies. On 
day 28 post immunization all six groups of mice were challenged with 0.1 ml of 100 LD50 
of P. multocida P52 by the intraperitoneal route. The LD50 of P. multocida was calculated 
by the method of REED and MUENCH (1938). The mortality pattern was recorded in each 
group and sera were collected on days 5 and 10 post challenge. 
Indirect enzyme linked immunosorbent assay (i-ELISA). i-ELISA was performed to 
determine antibody response, as per the method of NATALIA et al. (1992). Briefl y, OMP 
was coated on microtitre plate wells (Maxisorb® 96-well fl at bottom ELISA plate, Nunc, 
Denmark) at a concentration of 1 μg/mL at 4 °C overnight. Unbound sites were blocked 
with 1% BSA in PBS-Tween 20 (0.05%), pH 7.2. Test sera in a dilution of 1:100 were 
added in triplicate and reacted with coated antigen for 2 h at 25 °C. The bound antibody 
was then detected using 1:1000 dilutions of affi nity purifi ed goat anti-mouse IgG horse-
radish peroxidase (HRPO) conjugate (Bangalore Genei, India). The enzymatic reaction 
was assayed using orthophenylene diamine (Sigma, USA) and the change in intensity of 
the colour was determined at A492 nm by the ELISA reader (Tecan-sunrise). The antibody 
titres were calculated by the following formula:
 Log antibody titre = X+ (A-C/A-B) x D
where X = log dilution of the test sample, with A492 immediately higher than the cut-
off value; A = A492 of the test sample dilution immediately higher than the cut-off; B = A492 
of the test sample dilution immediately lower than the cut-off; C = Cut-off A492 (Mean 
A492 of the negative samples + 3x S.D.) and D = log dilution factor i.e. 1.
Statistical analysis. Antibody responses, as measured by i-ELISA, were analyzed by 
Student’s t test to fi nd the statistical signifi cance of the differences between the groups 
of mice.
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Results
Purifi cation of 34 kDa OmpH protein. The protein content in the OMP-rich extract of 
the P52 strain was 6.0 mg/ml. The OMP rich preparation of P. multocida P52 revealed the 
presence of OmpH as a 34 kDa protein band among other major OMPs, eluted as a single 
polypeptide band when subjected to SDS-PAGE.
Expression and purifi cation of P. multocida  recombinant OmpH protein. The cloning, 
expression and purifi cation of recombinant OmpH has been previously described (SINGH 
et al. 2009). PCR amplifi cation of ompH gene of P multocida P52 yielded the expected 
product of about 1 kb.
Nucleotide sequence accession number. The DNA sequence of the ompH gene of 
Pasteurella multocida P52 has been deposited in GeneBank under accession number 
HM117642. 
Challenge studies in mice. The protective ability of different immunogens in the 
challenge study showed 100% protection with OMP fraction used as a vaccine. The 
groups immunized with sonicated whole cell lysate and commercial vaccine showed 
a survival rate percentage of 83.33%. The recombinant OmpH group showed 63.67% 
survivability, as compared to the native OmpH group, that showed a 50% survival rate. 
100% mortality was recorded in the control group mice.
Antibody response studies. The humoral immune response, measured by i-ELISA of 
sera from mice inoculated with sonicated whole cell lysate, OMP, native 34 kDa OmpH, 
recombinant OmpH and commercial vaccine, is shown in Fig. 1.
In Group I (Sonicated whole cell lysate), there was a signifi cant increase (P<0.05, 
Student’s t test) in titres from d0 to d7, d14 and d21, with mean values (log10 titre) of 2.58, 
3.93 and 4.49 respectively, whereas the antibody response increased non-signifi cantly 
from d21 to d28 post immunization. 
In Group II (OMP fraction), there was signifi cant increase (P<0.05) in antibody 
response from d0 to d7, with titre values of 3.00 on d7, although a non-signifi cant 
increase in immune response was seen from d7 to d14. Further, there was a signifi cant 
rise in antibody titres up to d28, with log10 titre values of 4.04 and 4.41 on d21 and d28 
respectively.
In Group III (Native OmpH), there was signifi cant increase (P<0.05) in titres from d0 
to d7, with a mean titre of 3.70, while the antibody response increased non-signifi cantly 
from d7 to d14. Further, there was a signifi cant rise in antibody titres up to d28 with log10 
titre value of 4.23 and 4.67 on d21 and d28, respectively.
In Group IV (Recombinant OmpH), there was a signifi cant increase (P<0.05) in titres 
from d0 to d7 and d14 with titre values of 3.36 and 3.58, respectively. Antibody response 
further increased non-signifi cantly until d28 post immunization.
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Fig. 1. Humoral immune response measured by i-ELISA of sera from mice inoculated with 
sonicated whole cell lysate, OMP, native 34 kDa OmpH, recombinant OmpH and commercial 
vaccine.
In the positive control (Group V), there was a signifi cant increase (P<0.05) in titres 
from d0 to d7 and d14, with titres of 4.06 and 4.41 respectively, while antibody response 
further increased non signifi cantly up to d28. 
In Group VI (negative control), the value of the log10 titre remained constant (2.03) 
throughout the experimental schedule. 
Discussion
Vaccination against HS is widely practised in endemic areas but signifi cant outbreaks 
still occur (SHIVACHANDRA et al., 2011). To develop a superior quality vaccine, 
components of bacterial cells, such as OMPs, LPS, capsule and fi mbrial protein, have 
been studied. Amongst them, OMPs have been shown to play a predominant role in 
protective immunity and thus can be used as potential candidates.
In the present study, OmpH, in its native and recombinant form, was used as an 
immunogen in mice. 
In our previous study, the ompH gene of Pasteurella multocida P52 was cloned 
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to obtain the mature OmpH as a 313 amino acid polypeptide, with a predicted molecular 
mass of 33,760 Da (SINGH et al., 2011). In the present study, OMP rich extract revealed 34 
kDa as a major protein purifi ed by preparative SDS-PAGE, as reported previously (BRAR 
et al., 2010; HAMID and JAIN, 2008). 
No improvement in the expression profi le of the desired 34 kDa protein was obtained 
while studying expression kinetics. BHAT and JAIN (2010) studied the induction kinetics 
of 49 kDa recombinant OMP protein of Salmonella Typhi, in order to determine the time 
for optimal induction of the expressed protein. They found that maximum induction was 
obtained at 4 h after addition of 1.0 mM IPTG to the medium.
Mice were chosen as an experimental model for protection studies and monitoring 
humoral immune response through i-ELISA, since there is a direct correlation between 
antibody response and protection (DUA et al., 1978; KHARB and SHIV CHARAN, 2013). 
In the mouse protection test, survivability percentages of 83.33%, 100%, 50%, 
63.67% and 83.33% were observed in Groups I-V respectively, against 100% mortality in 
Group VI. LUO et al. (1997) reported that purifi ed native OmpH induced 100% protection 
but the recombinant induced little protection. In the present study, recombinant OmpH 
protein provided 63.67% protection in mice, as compared to native OmpH, which only 
induced 50% protection. LUO et al. (1997) purifi ed native protein through size exclusion 
chromatography for the experiment, whereas in the present study it was gel eluted. It 
is possible that during elution from denaturing PAGE, native protein could have lost 
some immunogenic epitopes. LEE et al. (2007) also studied the protective effi cacy of one 
full length and three short truncated fragments of recombinant OmpH protein in mice, 
and showed that the full length recombinant OmpH protein showed protection levels 
up to 70%, whereas, in truncated fragments the protection level was 30-50% against a 
homologous challenge. Moreover, BRAR et al. (2010) reported that 32 and 25 kDa gel eluted 
protein fractions, separately or in combination, did not provide any protection in mice. 
In the present study, OMP fraction induced 100% protection. BASAGOUDANAVAR et 
al. (2006) reported 100% protection in mice using OMP- Montanide and OMP-liposome 
vaccines in challenge experiments, thus confi rming the role of OMP in immunoprotection. 
KHARB and SHIV CHARAN (2010) investigated the role of OMPs in mice, showing 
100% protection upon intranasal challenge, and 84% protection following subcutaneous 
challenge, as compared to 84% mortality in the control. Similarly, BRAR et al. (2010) 
reported 100 percent protection in mice using whole OMP as a vaccine. However, 
SRIVASTAVA (1998) observed in their study that mice immunized with OMP vaccine 
showed a survival rate of 67% and concluded that although the level of protection from 
OMP was lower than the whole cell vaccine, i.e. 84% survival rate, it was above the 
acceptable level. Commercial vaccine and sonicated whole cell lysate induced 83.33% 
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survivability in the present study that was comparable to an 84% survival rate with whole 
cell vaccine of P. multocida, as reported by SRIVASTAVA (1998). 
In contrast to our fi ndings, TAN et al. (2010) observed 100% protection with 
recombinant 37 kDa OmpH in mice. But the route of immunization and challenge was 
I/P. Immunization with major OMP of Vibrio vulnifi cus resulted in protective antibodies 
giving 100% protection until d28 in a murine model (JUNG et al., 2005). BHAT and JAIN 
(2010) also reported 100% protection in mice with recombinant and native 49 kDa protein 
in Salmonella enterica serovar Typhimurium. 
BASAGOUDANAVAR et al. (2006) used OMP with adjuvants including dioleoyl 
phosphatidyl choline-based liposome and Montanide ISA206 water-in oil-in water 
emulsion, and observed that ELISA titres were similar on day-21 PI (log10 titre 4.5) with 
an increase in titre one week after boost (log10 titre 4.8). It increased further (log10 titre 5.1) 
by day-45 PI before becoming stationary by day-68. BRAR et al. (2010) observed a direct 
relationship between antibody titres and survival rate following immunization of mice 
with 32 and 25 kDa eluted proteins and whole OMP. The mice vaccinated with whole 
OMP were 100 percent protected, showing an ELISA log10 titre 3.1. In support of our 
fi ndings, KHARB and SHIV CHARAN (2010) reported that antibody responses increased 
signifi cantly on day 14 in their OMP and WCL groups (P<0.05). Antibody titres further 
increased signifi cantly on 21 dpi (P<0.01). Anamnestic antibody response was observed 
on 28 dpi. It continued to increase on 35 dpi. 
In our study, the commercial vaccine was initially found to be more immunogenic, 
giving the highest antibody titre until d14, as compared to sonicated whole cell lysate, 
OMP, native and recombinant OmpH, but in the later stages of the experiment, sonicated 
whole cell lysate, OMP and native OmpH were found to be as immunogenic as alum 
precipitated vaccine, with a sharp antibody response. On d28, all groups except Group 
IV (Recombinant OmpH), showed comparable titre values, indicating a similar antibody 
response. The challenge to the animals on d28 post immunization provided a booster to 
the immune response, resulting in an even higher antibody titre, as reported by PATI et 
al. (1996). Thus, it may be concluded that Native OmpH and OMP generated a delayed 
response. However, recombinant OmpH showed a weak antibody response in comparison 
to other preparations. 
Taking these observations together, it may be concluded that OMPs play an immuno-
protective role and possess strong potential for the development of a candidate subunit 
vaccine against HS. Further studies are required where this immunogenic fraction may 
be used as a booster dose after primary vaccination, to enhance the duration of protective 
immunity. The immunogenic protein may also be evaluated as a vaccine candidate through 
different routes of immunization, especially to induce mucosal immunity (KHARB and 
SHIV CHARAN, 2011).
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SAŽETAK
Istraživanje je provedeno s ciljem da se procijeni zaštitni učinak rekombinantnog proteina (OmpH) 
vanjske membrane bakterije Pasteurella multocida (B:2). Prirodni protein OmpH od 34 kDa bio je pročišćen od 
iscrpka bogatog OMP-om. Provedeno je kloniranje, ekspresija i pročišćavanje rekombinantnog OmpH.  Prvoj 
skupini miševa bio je primijenjen ultrazvučno obrađen stanični lizat. Drugoj skupini primijenjen je OMP, trećoj 
prirodni OmpH od 34  kDa, a četvrtoj rekombinantni OmpH. Peta skupina bila je pozitivna kontrola cijepljena 
komercijalnim cjepivom, dok je šesta skupina bila negativna kontrola. Stopa preživljavanja u I. skupini bila je 
83,33%, u II. skupini 100%, u III. 50%, u IV. 63,67% te u V. također 83,33%. U VI. skupini mortalitet je iznosio 
100%.  Titar serumskih IgG određivan je i-ELISA-om u mješavini uzoraka prikupljenih jednom tjedno od 30 
životinja iz svake skupine. U I. skupini ustanovljen je porast srednje vrijednosti titra specifi čnih protutijela 7. 
dana kada je iznosila  2,58 (titar log10), 14. dana kada je iznosila 3,93 i 21. dana kada je iznosila 4,49. U II. 
skupini značajni porast srednje vrijednosti titra specifi čnih protutijela dokazan je sedmoga dana 3,0, zatim 
21. dana 4,04 te 28. dana  4,41. U III. skupini dokazan je značajan porast srednje vrijednosti titra specifi čnih 
protutijela 7., 21. i 28. dana s vrijednostima 3,70, 4,23 i 4,67. U IV. skupini značajan porast titra dokazan je 
7. i 14. dana sa srednjim vrijednostima 3,36 i 3,58. U kontrolnih životinja značajan porast titra dokazan je 7. i 
14. dana s vrijednostima 4,06 i 4,41. Na osnovi prikazanih rezultata može se zaključiti  da OMP ima zaštitnu 
ulogu i veliku mogućnost da bude kandidat za razvitak podjediničnog cjepiva protiv  hemoragijske septikemije. 
Ključne riječi: Pasteurella multocida, OMP, OmpH, rekombinanta, cjepivo________________________________________________________________________________________
